This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.
This is a prospective, observational, population-based cohort study in US cystic fibrosis patients participating in the Cystic Fibrosis Patient Registry in order to assess the incidence of and risk factors for fibrosing colonopathy. Cystic fibrosis (CF) patients participating in the registry from participating sites, as well as new CF patients enrolled in the registry at these sites over a 2-year period, will serve as the base study population (estimated to include 24,500-25,000 cystic fibrosis patients between the first patient encounter documented in the registry from any participating site and the 31st of July 2014). Cystic fibrosis patients in the base study population will be followed at their regular clinical care visits and, any patients presenting over a 10-year period with signs and symptoms of suspected fibrosing colonopathy, based on a prospective definition, will be approached to obtain a study-specific informed consent for collection of additional data outside the standard registry data collection form in order to augment surveillance. Data routinely collected via the standard CF registry will be used to determine exposure to any specific pancreatic enzyme replacement therapy and to assess potential risk factors for the outcome of confirmed fibrosing colonopathy. An independent adjudication panel will be utilized to validate the diagnosis of fibrosing colonopathy based on a prospective case definition as well as decision rules.
Study Type
OBSERVATIONAL
Enrollment
17
pancreatic enzyme replacement therapy
pancreatic enzyme replacement therapy
pancreatic enzyme replacement therapy
pancreatic enzyme replacement therapy
pancreatic enzyme replacement therapy
pancreatic enzyme replacement therapy
Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
Children's Hospital of Alabama /ID# 78920
Birmingham, Alabama, United States
Alaska Medical Center /ID# 79256
Anchorage, Alaska, United States
Phoenix Children's Hospital /ID# 78906
Phoenix, Arizona, United States
University of Arizona Cancer Center - North Campus /ID# 78939
Tucson, Arizona, United States
Arkansas Children's Hospital /ID# 79265
Little Rock, Arkansas, United States
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving ZENPEP
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving ULTRESA
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving PERTZYE.
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving CREON
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving PANCREAZE
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients not receiving pancreatic enzyme therapy.
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving non-sponsor pancreatic enzyme replacement therapy
Fibrosing colonopathy is confirmed by an independent adjudication panel based on prospectively defined criteria.
Time frame: up to 10 years
Odds ratio (95% confidence interval) to quantify the association between possible risk factors and confirmed fibrosing colonopathy
Potential risk factors include demographics, medical history, and concurrent medications, including daily dosage and length of specific pancreatic enzyme replacement therapy.
Time frame: up to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Arkansas for Medical Sciences /ID# 76785
Little Rock, Arkansas, United States
Ucsd /Id# 105039
La Jolla, California, United States
Loma Linda University /ID# 79237
Loma Linda, California, United States
Miller Childrens Hospital /ID# 78896
Long Beach, California, United States
Kaiser Permanente Regional Met /ID# 79235
Los Angeles, California, United States
...and 113 more locations